Low-dose interferon-alpha in stage-I multiple myeloma and in IgM monoclonal gammopathy
Author:
- Eastern Cooperative Study Group on Monoclonal GammopathiesEGEastern Cooperative Study Group on Monoclonal Gammopathies
- 1 March 1992
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 64 (3) , 123-127
Abstract
Interferon (IFN)-a can induce objective responses in advanced-stage multiple myeloma (MM) and can delay disease progression in patients responsive to chemotherapy. We studied the effects of low-dose (3 MU daily) human recombinant IFN-α 2b for 6–12 months in 29 consecutive cases of previously untreated, stablephase, early stage, monoclonal gammopathy (MG) (23 cases of stage I MM and six cases of IgM MG). In 25/29 patients, the disease remained stable throughout the study period. A major objective response was observed in one of five cases of IgA MG. Normal Ig levels increased in all five cases of IgA MG. A significant disease progression occurred in 2/29 cases during the 1-year study period. These data showed that the objective response rate of early-stage MG to low-dose IFN was low and suggested that further investigation should focus on IgA MG.Keywords
This publication has 27 references indexed in Scilit:
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisoneBritish Journal of Haematology, 1990
- Interferon: A new strategy in the treatment of multiple myelomaEuropean Journal of Haematology, 1989
- Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCSEuropean Journal of Haematology, 1989
- High doses of natural α‐interferon (α‐IFN) in the treatment of multiple myeloma — A pilot study from the Myeloma Group of Central Sweden (MGCS)European Journal of Haematology, 1988
- Results of the mrc myelomatosis trials for patients entered since 1980Hematological Oncology, 1988
- Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocolCancer Treatment Reviews, 1988
- Treatment of multiple myeloma with an intensive 5‐drug combination or intermittent melphalan and prednisone; a randomised multicentre trialEuropean Journal of Haematology, 1987
- ALPHA INTERFERONS IN B‐CELL NEOPLASMSBritish Journal of Haematology, 1986
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979